Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New cholera vaccines.

J Holmgren1, J Clemens, D A Sack

  • 1Department of Medical Microbiology, University of Göteborg, Sweden.

Vaccine
|April 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cholera rapid diagnostic tests at the host-microbe interface: Key Considerations for Global Deployments.

medRxiv : the preprint server for health sciences·2025
Same author

Gold Standard Cholera Diagnostics Are Tarnished by Lytic Bacteriophage and Antibiotics.

Journal of clinical microbiology·2020
Same author

Toxins and virulence factors of enterotoxigenic Escherichia coli associated with strains isolated from indigenous children and international visitors to a rural community in Guatemala.

Epidemiology and infection·2014
Same author

Diarrhea burden due to natural infection with enterotoxigenic Escherichia coli in a birth cohort in a rural Egyptian community.

Journal of clinical microbiology·2014
Same author

A novel and simple mixture as point-of-use water treatment agent to produce safe drinking water.

Transactions of the Royal Society of Tropical Medicine and Hygiene·2014
Same author

Inhibited growth of common enteropathogenic bacteria in lactic-fermented cereal gruels.

World journal of microbiology & biotechnology·2014
Same journal

Retraction notice to "Effectiveness of prescription-based influenza vaccination services among older adults in Binzhou, China: A cluster-randomized controlled trial" [Vaccine 82 (2026) 128588].

Vaccine·2026
Same journal

Barriers and facilitators to COVID-19 vaccination programme implementation in Ireland: a qualitative study of implementation stakeholders using CFIR.

Vaccine·2026
Same journal

Immunogenicity and safety of a SARS-CoV-2 recombinant vaccine S-268024 booster vaccination versus NVX-CoV2373: Interim results from a phase 3, multicenter, randomized, observer-blind, active-controlled study.

Vaccine·2026
Same journal

Safety and immunogenicity of a reduced, homologous booster dose of the BNT162b2 mRNA COVID-19 vaccine: a single blind, randomized, non-inferiority follow-up trial.

Vaccine·2026
Same journal

Vaccination policies for healthcare personnel in Europe, 2026.

Vaccine·2026
Same journal

A historical overview of the anti-vaccine movement and its public health implications.

Vaccine·2026
See all related articles

New oral cholera vaccines are safe and effective for at least 3 years. These vaccines also offer protection against enterotoxigenic Escherichia coli diarrhea, improving global cholera control efforts.

Area of Science:

  • Vaccinology
  • Infectious Disease Epidemiology
  • Microbiology

Background:

  • Cholera remains a significant public health threat, particularly in developing nations.
  • Existing cholera vaccines have limitations in efficacy and duration of protection.
  • The need for safe, effective, and long-lasting cholera vaccines is critical for disease control.

Purpose of the Study:

  • To evaluate the safety and efficacy of a newly developed oral killed cholera vaccine.
  • To assess the duration of immunity conferred by the oral killed cholera vaccine.
  • To explore advancements in live attenuated cholera vaccine development.

Main Methods:

  • Development and administration of an oral killed cholera vaccine.
  • Assessment of intestinal antibacterial and antitoxic immunity.

Related Experiment Videos

  • Clinical trials to determine vaccine safety and protection duration.
  • Research into recombinant DNA techniques for live attenuated vaccine creation.

    • Main Results:

    • The oral killed cholera vaccine demonstrated complete safety.
    • The vaccine provided protection against cholera for a minimum of 3 years.
    • Substantial, albeit shorter-lasting, immunity against enterotoxigenic Escherichia coli diarrhea was observed.
    • Progress in developing a live attenuated cholera vaccine using recombinant DNA technology was reported.

    Conclusions:

    • Effective oral cholera vaccines offer a promising strategy for enhanced cholera control in the Third World.
    • The developed oral killed vaccine provides a safe and durable protective effect against cholera.
    • Further development of live attenuated vaccines holds potential for improved cholera prevention.